Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis
| Autor: | Randall F. D'Souza, Sreevalsan Sreebhavan, Ernst J. Wolvetang, Aneta Przepiorski, Jennifer A. Hollywood, Alan J. Davidson, Patrick T. Harrison, Teresa M. Holm |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cysteamine Cystinosis Induced Pluripotent Stem Cells Cystine Drug Evaluation Preclinical mTORC1 Mice SCID Cell Line 03 medical and health sciences chemistry.chemical_compound Mice 0302 clinical medicine Lysosome medicine Autophagy Animals Humans Everolimus PI3K/AKT/mTOR pathway Gene Editing business.industry TOR Serine-Threonine Kinases General Medicine medicine.disease Organoids Disease Models Animal 030104 developmental biology medicine.anatomical_structure Basic Research Amino Acid Transport Systems Neutral Phenotype Cystinosin chemistry Nephrology 030220 oncology & carcinogenesis Cancer research Heterografts Drug Therapy Combination CRISPR-Cas Systems business Lysosomes |
| Zdroj: | J Am Soc Nephrol |
| Popis: | BACKGROUND: Mutations in CTNS-a gene encoding the cystine transporter cystinosin-cause the rare, autosomal, recessive, lysosomal-storage disease cystinosis. Research has also implicated cystinosin in modulating the mTORC1 pathway, which serves as a core regulator of cellular metabolism, proliferation, survival, and autophagy. In its severest form, cystinosis is characterized by cystine accumulation, renal proximal tubule dysfunction, and kidney failure. Because treatment with the cystine-depleting drug cysteamine only slows disease progression, there is an urgent need for better treatments. METHODS: To address a lack of good human-based cell culture models for studying cystinosis, we generated the first human induced pluripotent stem cell (iPSC) and kidney organoid models of the disorder. We used a variety of techniques to examine hallmarks of cystinosis-including cystine accumulation, lysosome size, the autophagy pathway, and apoptosis-and performed RNA sequencing on isogenic lines to identify differentially expressed genes in the cystinosis models compared with controls. RESULTS: Compared with controls, these cystinosis models exhibit elevated cystine levels, increased apoptosis, and defective basal autophagy. Cysteamine treatment ameliorates this phenotype, except for abnormalities in apoptosis and basal autophagy. We found that treatment with everolimus, an inhibitor of the mTOR pathway, reduces the number of large lysosomes, decreases apoptosis, and activates autophagy, but it does not rescue the defect in cystine loading. However, dual treatment of cystinotic iPSCs or kidney organoids with cysteamine and everolimus corrects all of the observed phenotypic abnormalities. CONCLUSIONS: These observations suggest that combination therapy with a cystine-depleting drug such as cysteamine and an mTOR pathway inhibitor such as everolimus has potential to improve treatment of cystinosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|